

RESEARCH ARTICLE

qPCR assays to quantitate tRNA^{pyl} and pylRS expression in engineered cell linesAndrew Garcia, Gargi Roy, Christine Kiefer , Susan Wilson, Marcello Marelli *

Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, MD, United States of America

* marellim@medimmune.com OPEN ACCESS

Citation: Garcia A, Roy G, Kiefer C, Wilson S, Marelli M (2019) qPCR assays to quantitate tRNA^{pyl} and pylRS expression in engineered cell lines. PLoS ONE 14(5): e0216356. <https://doi.org/10.1371/journal.pone.0216356>

Editor: Floyd Romesberg, Scripps Research Institute, UNITED STATES

Received: December 5, 2018

Accepted: April 18, 2019

Published: May 9, 2019

Copyright: © 2019 Garcia et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: AG, GR, CK, SW and MM are employees of Medimmune LLC/AstraZeneca. Medimmune LLC/AstraZeneca provided support in the form of salaries for authors AG, GR, CK, SW and MM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: AG, GR, CK, SW and MM are employees of Medimmune LLC/AstraZeneca. The

Abstract

Non-natural amino acids (nnAA) contain unique functional moieties that greatly expand the available tool set for protein engineering. But incorporation of nnAAs requires the function of an orthogonal aminoacyl tRNA synthetase/tRNA pair. Stable cell lines expressing these components have been shown capable of producing gram per liter levels of antibodies with nnAAs. However, little has been reported on the genetic makeup of these cells. To gain a better understanding of the minimal requirements for efficient nnAA incorporation we developed qPCR methods for the quantitation of the key components. Here we describe the development of qPCR assays for the quantification of tRNA^{pyl} and pylRS. qPCR was chosen because it provides a large dynamic range, has high specificity for its target, and is a non-radioactive method used routinely for cell line characterization. Designing assays for tRNAs present challenges due to their short length (~72 nucleotides) and high secondary structure. These tRNA assays have a ≥ 5 log dynamic range with the tRNA^{pyl} assays being able to discern the mature and unprocessed forms of the tRNA^{pyl}. Cell line analysis showed tRNA^{pyl} was expressed at higher levels than the CHO-K1 endogenous Met and Phe tRNAs and that >88% of tRNA^{pyl} was the mature form.

Introduction

Over the last ten years bioconjugates have emerged as a promising new class of medicines that offer improved performance of therapeutics. Bioconjugations have been used extensively to improve the half-life of proteins (e.g. PEGylation) and more recently for the construction of antibody drug conjugates (ADCs) [1,2]. ADCs are a promising new class of engineered biotherapeutic that combines the targeting specificity of antibodies with potent cytotoxins for the treatment of cancers. Early ADCs were generated by targeting cysteine thiols, or the primary amine of lysine for payload conjugation. However, this strategy generated heterogenous ADCs that have shown variable payload stability and reduced therapeutic effect [3,4]. To address these limitations technologies have emerged that enable site-specific modifications of target proteins to better control the homogeneity and stability of the products. One of the most attractive methods involves the site-specific incorporation of non-natural amino acids (nnAAs) containing moieties that enable biorthogonal conjugation chemistries [2,5–11].

authors confirm that this does not alter our adherence to PLOS ONE policies on sharing data and materials.

Biorthogonal conjugation methods including oxime, Diels-Alder and click cycloaddition have all shown efficient conjugate formation and improved stability of the conjugates over the commonly used thiol-maleimide conjugations.

The drawback to using nnAAs lies in the production of proteins containing these nnAAs. Expression systems in *E. coli*, yeast, mammalian cells (CHO and HEK293), and cell free expression systems have been developed and shown efficiency in nnAA incorporation [6, 8, 12–16]. Of these, mammalian cell expressions have the distinct advantage that they conform with conventional fermentation processes, contain a reliable glycosylation pattern, and are generally devoid of endotoxin. Thus, great effort has been dedicated to developing cell lines that are capable of high titer expression of nnAA containing proteins. Stable cell lines expressing orthogonal aminoacyl tRNA synthetase/tRNA pairs have shown yields exceeding 1g/L [7, 17]. However, a good understanding of the minimal expression requirements of aaRS and its tRNA to enable efficient amber suppression is lacking. While the detection and quantification of aaRS expression is straightforward, the same cannot be said of tRNA. The measurement of tRNA is challenging due to its short size, and extensive secondary structure which restricts available qPCR probe sites. In addition, mature cytosolic tRNA, which averages 72 nucleotides is derived from a larger precursor molecule that undergoes 3' and 5' processing, and in eukaryotic cells is further modified with a 3' trinucleotide (CAA) to generate a functional tRNA [18]. Gel based methods requiring hybridization have been used to quantify the expression and assess the level of maturation of tRNAs [19–21]. While this method allows for the quantitation of aminoacylated, free, unprocessed and mature tRNA, it requires radioactive probes and is of low throughput. Molecular approaches to quantify specific tRNAs like four-leaf clover qPCR have been developed, but require large amounts of RNA, has a limited dynamic range, and requires multiple enzymatic steps [22].

We have developed a CHO-based expression system for the expression of biotherapeutics containing nnAAs [7]. The cells utilize the pyrrolysine tRNA synthetase (pylRS), derived from *Methanosarcina mazei*, with specificity for a nnAA and its cognate pyrrolysine tRNA (tRNA^{pyl}) which directs the nnAA to amber codons in the gene of interest [11]. However, the identification of engineered cells capable of efficient nnAA incorporation required extensive functional screening using reporter constructs to assess amber suppression. The development of these cell lines showed that high tRNA gene copy numbers were needed to achieve the desired nnAA incorporation efficacy in both transient and stable cell lines. To understand the requirements for efficient nnAA incorporation we utilized a qPCR method useful for the quantitation of these genes. The assays were developed to assess both the DNA copy number and RNA expression levels of pylRS and its cognate tRNA^{pyl} in cell lines capable of amber suppression. This method provides a necessary tool for the characterization of these cells and the determination of the minimum requirements for efficient amber suppression in host cells.

Materials and methods

RNA and DNA isolation

CHO cells selected for RNA and DNA isolation were grown in suspension in CD-CHO medium (LifeTechnologies) to a viable density of $1\text{--}2\times 10^6$ cells/mL. All cultures were grown at 37°C in shake flasks, in an environment controlled shaking incubator maintaining 6% CO₂, and 80% humidity (Multitron HT, Infors). Culture volumes containing 5×10^6 cells were subjected to centrifugation, medium was discarded, and pellets frozen at -80°C. Total RNA (tRNA, mRNA and rRNA) was isolated from frozen cell pellets consisting of 5×10^6 CHO cells using the mirVANA miRNA Isolation kit (Ambion) following the manufacturer's recommendations. Contaminating DNA was removed from the purified RNA samples using a DNA

removal kit (Ambion). Genomic DNA (gDNA) was isolated from frozen cell pellets using the AllPrep DNA/RNA Mini Kit (Qiagen). For each gDNA isolation 5×10^6 cells were lysed in 600 μ l lysis buffer and purified following the manufacturer's instructions.

Plasmid DNA

pCEP4-pylRS, pylRS gene was cloned under control of the CMV promoter in pCEP4 (Life-Technologies). pBS-tRNA^{pyl}, pBluescript SKII (Stratagene) containing a the tRNA^{pyl} gene.

Primer design and oligomers

The primers and probes used in this study were custom designed based on available gene sequences. tRNA^{pyl} oligo (72bp = 1.35×10^{10} copies/ng oligo), tRNA^{pyl} unprocessed oligo (87bp = 1.12×10^{11} copies/ng oligo), CHO-K1 tRNA^{met} oligo (72bp = 1.35×10^{10} copies/ng oligo) and CHO-K1 tRNA^{phe} oligo (73bp = 1.33×10^{10} copies/ng oligo). The primers and probes for CHO-K1 Beta-2 microglobulin (CHO-K1 B2M) were designed by entering a single CHO-K1 B2M exon from GenBank NW_006871970 into ABI's "Custom Taqman Assay Design Tool." All DNA oligos were synthesized by IDT and DNA probes were synthesized by ABI. The 18S rRNA (18S) assay was purchased from ABI (Hs999999_01) and used at 1X final concentration in qPCR assays and produces an amplicon of 187bp. No primer sequence information is available for the 18S purchased from ABI.

qPCR of gDNA

gDNA samples were analyzed using the Taqman Fast Universal PCR Master Mix (ABI). All assays were performed on the 7900HT Fast Real-Time PCR instrument using a "fast 96 well plate." Thermocycler conditions were 1 cycle of 95 °C for 20sec followed by 40 cycles of 95 °C for 1sec and 60 °C for 20sec. Each reaction contained 10ng gDNA, 1 μ M forward primer, 1 μ M reverse primer and 0.25 μ M probe. All samples were analyzed in triplicate.

qRT-PCR of RNA

RNA samples were analyzed by one-step qRT-PCR method using the Express One-Step SuperScript qRT-PCR with Pre-mixed ROX kit (LifeTechnologies). Reverse Transcription was performed using gene specific primers. For tRNA qRT-PCR, purified total RNA, primers and water were mixed and incubated at 80 °C for 5 min, then allowed to cool to room temperature. Buffers and SuperScript qRT were added prior to the qRT-PCR incubations. All assays were performed on the 7900HT Fast Real-Time PCR instrument using a "fast 96 well plate" with each reaction containing 5ng RNA in a 20 μ l reaction volume. Thermocycler conditions were 1 cycle of 60 °C for 15min for Reverse Transcription then 1 cycle of 95 °C for 20sec followed by 40 cycles of 95 °C for 1sec and 60 °C for 20sec. All samples were analyzed in triplicate.

Cell line construction

Cell lines stably expressing pylRS and tRNA^{pyl} were constructed as described in [7]. Briefly, Chinese hamster ovary cells (CHO), adapted to serum free suspension growth, were transfected with the plasmid pCLD-RS-18xtRNA, encoding pylRS under control of the CMV promoter, 18 tandem repeats of the tRNA^{pyl} under control of the U6 snRNA promoter, and a puromycin resistance cassette. Transfected cells were grown in CD-CHO medium containing puromycin and survivors functionally characterized for amber suppression. To do this, mRNA encoding an RFP-GFP fusion, which contains an amber stop codon interrupting the RFP and GFP coding regions, was transfected into these cells. With this reporter all transfected cells

express RFP (RFP+/GFP-), but only cells capable of amber suppression express the RFP-GFP fusion (RFP+/GFP+) that can be readily observed and quantified by flow cytometry. The ratio of GFP:RFP may be indicative of the amber suppression efficacy in each of the cell lines. Thus, cells with the highest GFP:RFP ratios were selected for characterization.

Results

Testing assays for nnAA components on plasmid DNA

We set out to establish assays to determine the gene copy number and relative expression of pylRS and tRNA^{pyl} genes in engineered cell lines selected for their activity. While the assay for pylRS is straightforward, the high secondary structure of tRNA posed a challenge for qPCR. Thus, we began by developing a qPCR assay using plasmid DNA encoding the tRNA^{pyl} or pylRS as a template. This allowed us to test conditions without the confounding effect of tRNA structure. For each assay gene specific primer sets (Table 1) were used with a titration of the template DNA. The data shows a linear relationship between Ct and the log of plasmid copies ranging from 300 to 3×10⁸ copies for the tRNA^{pyl} gene, and 300–3×10⁷ for pylRS (Fig 1). For reference, 1ng of the pCEP4-pylRS (11,545bp) plasmid represents 8.44×10⁷ copies of the pylRS gene; and 1ng of pBS-tRNA^{pyl} (3,287bp) contains 2.97×10⁸ copies of the tRNA gene. In each case we observed a coefficient of determination (R²) approaching 1 and a slope approaching of -3.3. These data show that the qPCR assay has acceptable efficiency through this linear range and indicates that the primer/probe sets are adequate for the qPCR of these genes.

Testing tRNA assays on DNA oligos

Next, we tested the qPCR assay using DNA oligos as templates because they are expected to exhibit secondary structure consistent with cellular samples. In addition, tRNA undergoes

Table 1. Primers, probes, DNA oligo templates.

tRNA ^{pyl}	Forward	GGAAACCTGATCATGTAGATCG
	Reverse	GGAAACCCCGGAATC
	Probe	FAM- ACCCGGCTGAACGGATTTAGAGTC -TAMRA
tRNA ^{pyl} unprocessed*	Reverse	CGCACTGTCCGGAAC
pylRSwt	Forward	ATCAAGCACCATGAGGTGTC
	Reverse	ACCGCTTGCAAGTCTTTC
	Probe	FAM- CCAAGATCTACATCGAGATGGCCTGC -TAMRA
CHO-K1 tRNA ^{met}	Forward	GCAGAGTGGCGCAGC
	Reverse	GTTTCGATCCATCGACCTC
	Probe	FAM- GGGCCAGCAGCCTTCC -TAMRA
CHO-K1 tRNA ^{phe}	Forward	GAAATAGCTCAGTTGGGAGA
	Reverse	TGAAACCCGGATCGAA
	Probe	FAM- CGTTAGACTGAAGATCTAAAGGTCCTGG -TAMRA
CHO-K1 B2M	Forward	CGAGCTGTTGAAGAATGGAAAGAAG
	Reverse	CGTGTGAGCCAAAAGATAGAAAGAC
	Probe	FAM- ACAAAGTCGAGCTGTCAGATCT-NFQ
tRNA ^{pyl}	cDNA	CGGAAACCCCGGAATCGAACCCGGCTGAACGGATTTAGAGTCCATTTCGATCTACATGATCAGGTTTCC
tRNA ^{pyl} unprocessed	cDNA	AAAAAACCCTGCTTGTCCGAAACCCCGGAATCTAACCCGGCTGAACGGATTTAGAGTCCATTTCGATCTACATGATCAGGTTTCC
CHO-K1 tRNA ^{met}	cDNA	TAGCAGAGGATGGTTTCGATCCATCGACCTCTGGGTTATGGGCCAGCAGCCTTCCGCTGCGCCACTCTGCT
CHO-K1 tRNA ^{phe}	cDNA	TGCTGAAACCCGGGATCGAACCCAGGACCTTTAGATCTTTCAGTCTAACGCTCTCCAACTGAGCTATTTTCAGC

*tRNA^{pyl} and tRNA^{pyl} unprocessed use the same forward primer and probe.

<https://doi.org/10.1371/journal.pone.0216356.t001>




Fig 1. qPCR assay performance on plasmid DNA. The tRNA^{pyl} and pylRSwt qPCR assays were tested with a tenfold serial dilution of their respective plasmids spanning $300-3 \times 10^8$ copies. Graphing the Ct versus the log of plasmid copies demonstrates a linear range of $300-3 \times 10^8$ copies for tRNA^{pyl} and $300-3 \times 10^7$ copies for pylRSwt. A simple linear regression shows R² values approaching 1 and slope values close to -3.3.

<https://doi.org/10.1371/journal.pone.0216356.g001>

extensive processing to its mature and active form. Thus, DNA oligos encoding the cDNAs of fully processed mature tRNA^{pyl} and the unprocessed tRNA^{pyl} were synthesized and used as templates using the primer pairs and probes described above (Fig 2A). Synthesized DNA oligos were the only materials available that we could control for quantity and sequence and are representative of a 100% efficient reverse transcription reaction. Assays for endogenous CHO-K1 tRNA^{met} and tRNA^{phe} were designed to gauge expression levels of tRNA^{pyl} relative to natively expressed tRNAs. CHO-K1 tRNA^{met} and tRNA^{phe} were chosen for their limited codon representation, specifically tRNA^{met} has a single codon, ATG, and the tRNA^{phe} has two codons, TTT and TTC. As previously described, the qPCR assays were conducted against a ten-fold serial dilution of DNA oligo spanning $300-3 \times 10^8$ copies. All four tRNA assays showed acceptable slope and R² values with linearity from $300-3 \times 10^8$ DNA oligo copies (Fig 2B–2E).

It should be noted that the amplicon for the tRNA^{pyl} assay is contained in both the tRNA^{pyl} and tRNA^{pyl} unprocessed DNA oligos and will amplify both mature and unprocessed tRNA^{pyl} (total tRNA^{pyl}). To examine the specificity of the tRNA^{pyl} and tRNA^{pyl} unprocessed assays, both assays were run against a ten-fold serial dilution of tRNA^{pyl} and tRNA^{pyl} unprocessed DNA oligos spanning $300-3 \times 10^8$ copies of DNA oligo (Table 2). The assay for total tRNA^{pyl} yielded similar Ct values for both the tRNA^{pyl} and tRNA^{pyl} unprocessed DNA oligos. On the other hand, the tRNA^{pyl} unprocessed assay, shows a significant difference in Ct values between the tRNA^{pyl} and tRNA^{pyl} unprocessed DNA oligos. The increase in Ct of 13 corresponds to a reduction in sensitivity of 8000-fold, demonstrating that the tRNA^{pyl} unprocessed assay is relatively insensitive to mature tRNA^{pyl}. Mature tRNA^{pyl} levels were therefore calculated as the difference between tRNA^{pyl} and tRNA^{pyl} unprocessed.

Testing assays on cell line samples

Having established a quantitative qPCR assays for both tRNA^{pyl}, tRNA^{pyl} unprocessed and pylRS on DNA templates, we next set out to establish the conditions for quantifying RNA derived from cellular material derived from a cell line previously characterized for amber suppression activity [7]. For expression analysis this requires the establishment of an RT step to




Fig 2. qPCR assay performance on single stranded DNA oligos corresponding to their target cDNA. (A) Sequence of DNA oligos with the qPCR primers in blue and the qPCR probes in red. 5'-3' orientation is shown by the direction of the arrows. The position of the primers and probe for both mature and unprocessed tRNA^{pyl} are shown on the cloverleaf schematic of the tRNA. The primers for mature tRNA^{pyl} quantify total tRNA^{pyl} (mature and unprocessed). The reverse primer for unprocessed tRNA^{pyl} is specific for this species. (B) tRNA^{pyl} assay with the tRNA^{pyl} DNA oligo. (C) tRNA^{pyl} unprocessed assay with the tRNA^{pyl} unprocessed DNA oligo. (D) CHO-K1 tRNA^{met} assay with the CHO-K1 tRNA^{met} DNA oligo. (E) CHO-K1 tRNA^{phe} assay with the CHO-K1 tRNA^{phe} DNA oligo. The qPCR assays were tested using a tenfold serial dilution of their respective DNA oligo spanning 300–3×10⁸ copies. Plotting the Ct versus the log input of DNA oligo copies show that all qPCR assays have a linear range of 300–3×10⁸ with R² values approaching 1 and slopes near -3.3.

<https://doi.org/10.1371/journal.pone.0216356.g002>

Table 2. Specificity of tRNA^{Asp} and tRNA^{Asp} unprocessed qPCR assays on single stranded DNA oligo.

	tRNA ^{Asp}		tRNA ^{Asp} unprocessed	
	assay		assay	
tRNA ^{Asp}	Mean	Std Dev	Mean	Std Dev
cDNA oligo	Ct	Ct	Ct	Ct
3x10E8 copies	10.71	0.02	24.28	0.12
3x10E7 copies	14.47	0.09	27.84	0.02
3x10E6 copies	17.98	0.03	31.13	0.25
3x10E5 copies	21.90	0.15	34.71	0.23
3x10E4 copies	25.27	0.16	37.52	0.08
3x10E3 copies	28.47	0.11	ND	ND
3x10E2 copies	31.26	0.08	ND	ND
H2O	ND	ND	ND	ND
	tRNA ^{Asp}		tRNA ^{Asp} unprocessed	
	assay		assay	
tRNA ^{Asp} unprocessed	Mean	Std Dev	Mean	Std Dev
cDNA oligo	Ct	Ct	Ct	Ct
3x10E8 copies	10.65	0.40	11.64	0.55
3x10E7 copies	14.93	0.22	15.29	0.05
3x10E6 copies	17.97	0.08	18.35	0.01
3x10E5 copies	21.75	0.21	21.67	0.09
3x10E4 copies	25.16	0.15	24.64	0.05
3x10E3 copies	28.35	0.26	27.88	0.02
3x10E2 copies	31.14	0.26	30.93	0.06
H2O	37.99	1.41	ND	ND

ND, not detected

<https://doi.org/10.1371/journal.pone.0216356.t002>

convert RNA to cDNA prior to amplification and DNase treatment to remove contaminating genomic DNA. Gene specific primers were used for reverse transcription since the tRNAs have no binding site for oligo dT, and random hexamers do not transcribe all the required tRNA sequences for PCR amplification. As previously mentioned the high secondary structure of tRNA was expected to present a challenge. Indeed, RT-PCR reactions of cellular derived material showed equal values for both mature and unprocessed tRNA^{Asp}. The observation that the majority of the tRNA^{Asp} was in unprocessed form was contrary to our expectations and we hypothesized that the secondary structure of the mature tRNA^{Asp} was inhibiting efficient primer binding. To denature the secondary structure of the tRNA^{Asp} prior to RT, an 80°C incubation step was implemented to allow primer annealing and reverse transcription. Prior to the inclusion of the 80°C incubation step, the unprocessed form constituted almost 100% of tRNA^{Asp} signal obtained. However, after the 80°C incubation step it accounted for only 10% of tRNA^{Asp} signal. This change in percentage of signal from the unprocessed form suggests that the reverse transcriptase step is efficient. The final assay for RNA is a one-step RT-qPCR and the data shown is reported as a ratio relative to 18S ribosomal RNA (18S). For the purposes of our RNA assays we chose to use a single gene, 18S, for normalization. There is always the concern that cell treatment will alter expression levels of your normalizing gene however, in our experience, the high expression of 18S provides a buffer against such variations. Having multiple normalizers (ie GAPDH and 18S) would require extensive effort to make sure that the expression levels of the normalizers are not being differentially impacted by cell treatments. Throughout this manuscript RNA and tRNA expression levels are referred to as expression

ratios that are calculated using the following formula:

$$Expression\ Ratio = 2^{(-\Delta Ct)} \text{ where } \Delta Ct = (Target\ Mean\ Ct) - (18S\ Mean\ Ct)$$

Having established an effective method for measuring both mature and unprocessed tRNA^{pyl} total RNA we set out to test the assay on material derived from cells. To do this we isolated RNA from six different clonal cell lines derived from a host capable of amber suppression [7]. Each subclone was initially characterized for amber suppression activity by transfection of an mRNA construct encoding RFP-GFP containing an amber codon between the two fluorescent proteins (Fig 3A). The transfected cells were exposed to nnAA and the fluorescent proteins quantified by flow cytometry (Fig 3B). All transfected cells express the RFP reporter, but only cells capable of amber suppression express an RFP-GFP fusion. The ratio of GFP:RFP may be indicative of the pylRS/tRNA^{pyl} system activity. Thus, six clones (A-F), positive for amber




Fig 3. Quantifying RNA expression levels of unprocessed and mature tRNA^{pyl} in cell lines. (A) A reporter mRNA construct was designed to assess amber suppression activity. The reporter encodes an RFP-GFP fusion interrupted by an amber stop codon. All transfected cells show RFP expression, but only amber suppression competent cells express the RFP-GFP fusion. (B) Six clones isolated from an amber suppression competent host were transfected with the RFP-GFP mRNA and exposed to nnAA. Cells were grown for 24 h, and fluorescence expression examined by flow cytometry. Six positive clones showing RFP and GFP signals were identified. A cell line showing no GFP expression is shown for comparison (Neg). (C) RNA from the six amber suppression competent cell lines (A-F) was examined by the tRNA^{pyl} and tRNA^{pyl} unprocessed assays to quantify the extent of tRNA^{pyl} processing. (D) A schematic representation of the workflow for isolating and analyzing nucleic acids from cell lines. The data show that mature tRNA^{pyl} constitutes >88% of the tRNA^{pyl} forms present in the samples and indicate efficient processing of the tRNA^{pyl} in CHO cells.

<https://doi.org/10.1371/journal.pone.0216356.g003>

suppression, were selected to examine the tRNA and pylRS content. The data show that these stable cell lines have high expression levels of the tRNA^{pyl} with ratios relative to 18S ranging from 0.29 to 1.11 and with approximately 90% of the tRNA^{pyl} in its mature form (Fig 3C and Table 3). Interestingly, endogenously expressed tRNA^{phe} show expression ratios between 4–9×10⁻⁴ and tRNA^{met} between 1.44–2.73×10⁻³ (Fig 4 and Table 4). These levels are as much as 2000-fold lower than tRNA^{pyl} levels indicating that our engineered cells are high expressers of the tRNA^{pyl} which may be necessary to enable efficient amber suppression with nnAAs.

DNA copy number

Complementary assays to quantify the gene copy number of pylRS using qPCR assays were developed to gain further insight into the content of these engineered cells and examine the relationship between DNA copy number and RNA expression levels of the exogenous genes. Standard qPCR assays were used for both tRNA^{pyl} and pylRS using the same primer sets described above. In addition, a primer set specific for CHO-K1 B2M was synthesized to serve as a standard for genomic copy quantitation (and assuming 2 copies of CHO-K1 B2M per genome). In this text DNA copy number calculations are referred to as Copy Number and are determined with the following formula:

$$\text{Copy Number} = 2^{(-\Delta Ct)} \text{ where } \Delta Ct = (\text{Target Mean Ct}) - (\text{CHOK1 B2M Mean Ct})$$

A gene specific primer set was used with a serial dilution of CHO-K1 genomic DNA spanning 0.025–102.4 ng gDNA. This range reflects the quantities of gDNA that are expected to be loaded into the assay. The CHO-K1 B2M assay has acceptable slope and R² values with linearity from 0.025–102.4 ng gDNA (Fig 5).

As all the pylRS/tRNA^{pyl} expressing cells are from the same parental cell line, the expectation is that there will be no variation on CHO-K1 B2M copy number and all DNA copy number analyses are reported relative to CHO-K1 B2M. Relative copy number was deemed sufficient to examine how the copy number varied among cell lines. Thus, our stable cell lines were analyzed for pylRS and tRNA genomic copies. The data show that the tRNA^{pyl} copy number varies substantially from 62–560 copies while the pylRS had a much narrower range from 4–22 copies (Table 5). As the plasmid used for generating this cell line has a 1:18 ratio of pylRS:tRNA^{pyl} we expected this ratio to be observed in our stable cell lines (Table 6). Indeed, this ratio is generally retained in all cell lines suggesting that the integrating plasmids are generally intact. Two exceptions, Clone D and Clone F both show greater tRNA^{pyl} copy numbers than expected based on the numbers of pylRS indicating that some cell lines may, in the course of integrating the DNA into the genome, introduce only a portion of the tRNA^{pyl} containing

Table 3. Quantifying RNA expression levels of unprocessed and mature tRNA^{pyl} in cell lines.

Cell Line	tRNA ^{pyl} assay			tRNA ^{pyl} unprocessed assay			tRNA ^{pyl}	
	Mean Ct	Std Dev Ct	Expression Ratio	Mean Ct	Std Dev Ct	Expression Ratio	Mature	Unprocessed
clone A	17.27	0.25	1.11E+00	20.72	0.34	1.02E-01	90.8%	9.2%
clone B	18.56	0.21	2.95E-01	21.80	0.27	3.11E-02	89.5%	10.5%
clone C	16.84	0.08	8.07E-01	20.02	0.26	8.96E-02	88.9%	11.1%
clone D	17.63	0.28	5.45E-01	21.33	0.40	4.18E-02	92.3%	7.7%
clone E	17.13	0.23	4.53E-01	20.44	0.34	4.55E-02	90.0%	10.0%
clone F	16.57	0.12	8.36E-01	19.83	0.17	8.69E-02	89.6%	10.4%

tRNA expression ratios are reported relative to 18S rRNA.

<https://doi.org/10.1371/journal.pone.0216356.t003>




Fig 4. Quantifying RNA expression levels of native CHO-K1 tRNAs, tRNA^{pyl} and pylRSwt in engineered cell lines. RNA from six stable cell lines expressing pylRS/tRNA^{pyl} were assayed for endogenous tRNA^{phe}, tRNA^{met}, as well as tRNA^{pyl} and pylRSwt. The data demonstrate that pylRSwt is expressed at comparable levels to the endogenous CHO-K1 tRNA. tRNA^{pyl} is expressed at ~1000-fold higher levels than endogenous tRNA.

<https://doi.org/10.1371/journal.pone.0216356.g004>

Table 4. Quantifying RNA expression levels of native CHO-K1 tRNAs, tRNA^{pyl} and pylRSwt in cell lines.

Cell Line	tRNA ^{pyl} assay			tRNA ^{phe} assay			tRNAm ^{et} assay		
	Mean	Std Dev	Expression	Mean	Std Dev	Expression	Mean	Std Dev	Expression
	Ct	Ct	Ratio	Ct	Ct	Ratio	Ct	Ct	Ratio
clone A	17.27	0.25	1.11E+00	27.44	0.47	9.67E-04	26.21	0.36	2.27E-03
clone B	18.56	0.21	2.95E-01	26.99	0.39	8.55E-04	25.31	0.33	2.73E-03
clone C	16.84	0.08	8.07E-01	26.66	0.12	8.98E-04	25.06	0.35	2.72E-03
clone D	17.63	0.28	5.45E-01	27.30	0.04	6.67E-04	25.88	0.40	1.79E-03
clone E	17.13	0.23	4.53E-01	27.04	0.19	4.71E-04	24.75	0.14	2.30E-03
clone F	16.57	0.12	8.36E-01	26.73	0.13	7.29E-04	25.74	0.45	1.44E-03
	pylRSwt assay			18s assay					
	Mean	Std Dev	Expression	Mean	Std Dev				
Cell Line	Ct	Ct	Ratio	Ct	Ct				
clone A	26.55	0.27	1.79E-03	17.42	0.15				
clone B	27.60	0.08	5.58E-04	16.80	0.02				
clone C	25.86	0.18	1.56E-03	16.54	0.10				
clone D	26.78	0.26	9.58E-04	16.75	0.22				
clone E	26.40	0.13	7.32E-04	15.98	0.04				
clone F	25.00	0.07	2.42E-03	16.31	0.10				

tRNA^{phe}, tRNAm^{et}, tRNA^{pyl}, and pylRSwt expression ratios are reported relative to 18S rRNA.

<https://doi.org/10.1371/journal.pone.0216356.t004>




Fig 5. CHO-K1 B2M assay performance on CHO-K1 genomic DNA. The CHO-K1 B2M qPCR assay was tested against a fourfold serial dilution of CHO-K1 genomic DNA spanning 0.025–102.4 ng gDNA. Graphing the Ct versus the log of plasmid copies demonstrates a linear range of 0.025–102.4 ng gDNA with R² values approaching 1 and slope values close to -3.3.

<https://doi.org/10.1371/journal.pone.0216356.g005>

plasmid. The tight range of Ct values for CHO-K1 B2M validate the initial assumption that there is no difference in CHO-K1 B2M copies between the cell lines.

We also examined the correlation between DNA copy number and RNA expression level of both tRNA^{pyl} and pylRS (Fig 6A). For each cell line the genomic copy number of pylRS and tRNA^{pyl} were plotted against their corresponding expression level determine by RT-qPCR. For the most part we observed that cells with increased genetic copy numbers also showed increased expression levels for both pylRS and tRNA^{pyl} with notable exceptions. Clones A, B and C showed elevated tRNA^{pyl} expression ratios relative to their tRNA^{pyl} gene copy numbers; a trend that was also observed with pylRS suggesting that locus of integration may affect expression of these genes.

The biological impact of tRNA^{pyl} and pylRS expression on amber suppression efficiency was examined by comparing these levels with the GFP:RFP ratios obtained for each cell line in a functional assay (Fig 3B). the GFP:RFP ratios were determined using the geometric mean data from GFP and RFP by flow cytometry. The GFP levels measure amber suppression while

Table 5. Quantifying gene copy number in genomic DNA.

Cell Line	tRNA ^{pyl}			pylRSwt			CHO-K1 B2M	
	Mean Ct	Std Dev Ct	Copy Number	Mean Ct	Std Dev Ct	Copy Number	Mean Ct	Std Dev Ct
clone A	19.75	0.16	212.1	23.91	0.03	11.9	27.48	0.08
clone B	21.07	0.08	62.7	24.96	0.02	4.2	27.04	0.05
clone C	20.11	0.18	142.6	24.21	0.11	8.3	27.27	0.06
clone D	18.63	0.22	393.1	23.63	0.10	12.3	27.25	0.04
clone E	19.46	0.10	249.1	23.73	0.07	12.9	27.42	0.10
clone F	18.42	0.24	560.0	23.06	0.01	22.4	27.54	0.16

DNA copy number was determined relative to CHO-K1 B2M.

<https://doi.org/10.1371/journal.pone.0216356.t005>

Table 6. Comparing the observed tRNA^{pyl} copy number to the predicted tRNA^{pyl} copy number.

Cell Line	pylRSwt observed	tRNA ^{pyl} observed	tRNA ^{pyl} predicted
clone A	11.9	212.1	214.2
clone B	4.2	62.7	75.8
clone C	8.3	142.6	149.3
clone D	12.3	393.1	221.7
clone E	12.9	249.1	232.2
clone F	22.4	560.0	402.7

Copy numbers are reported relative to CHO-K1 B2M.

<https://doi.org/10.1371/journal.pone.0216356.t006>

RFP levels represent total expression of the reporter. The ratio of GFP:RFP may be indicative of amber suppression efficacy while accounting for differences in expression of the reporter in the different cell lines. In general, the data shows that higher levels of tRNA^{pyl} and pylRS results in increased amber suppression efficacy (Fig 6B and Table 7). It should be noted that transient expression experiments provide a useful, but limited measure of the expression potential of cells due to the short and transient nature of the assay. A better understanding of the true potential of these stable cell lines will need to be assessed using stable expression of very high expressing targets which exceed the capacity of the amber suppression system.

Next, we tested the specificity and reproducibility of the assays. To test specificity, we analyzed RNA and gDNA from a parental cell line (not-transfected with tRNA^{pyl} or pylRS) and two clones, clones 1 and 2, created by transfecting the parental cell line with tRNA^{pyl} and pylRS (S1 Table). The RNA data for tRNA^{pyl} and pylRS show expression in the transfected clones but not in the parental line, while the 18S signal is similar across all three cell lines. The gDNA data yields similar results with tRNA^{pyl} and pylRS having good signal in the transfected clones and little to no signal in the parental, while the CHO-K1 B2M signal is similar across all three cell lines. The consistent expression of the normalizer genes combined with the differential expression of tRNA^{pyl} and pylRS genes demonstrates that the assays are specific for tRNA^{pyl} and pylRS.

To demonstrate the reproducibility of this assay, a single prep of RNA or gDNA, isolated from a transfected cell line, was examined in triplicate on three consecutive days using an identical set up (S2 Table). The Mean Ct and Std Dev Ct values for the triplicates on the plate demonstrate the reproducibility within triplicates. The averages and standard deviations were then calculated across all the days and for each assay. The small standard deviation values for all the assays with RNA and gDNA templates demonstrates the reproducibility of these assays.

Discussion

A vast number of nnAAs have been developed that provide building blocks for protein engineering with unique functional chemistries. This repertoire of nnAAs provides a means for the generation of protein therapeutics with enhanced functionality, and thus hold great promise in producing and potentiating new drugs for the treatment of human disease. However, despite significant advances, the productivity of systems capable of site-specific nnAA incorporation has prevented its widespread use. Genetically encoding nnAA, in both in vitro and in vivo systems, requires the concerted function of an orthogonal aminoacyl tRNA synthetase and its cognate tRNA. In vitro expression systems have successfully addressed many of the limitations, but this methodology requires dedicated cell free expression facilities [8]. On the other hand, cell-based systems have been developed that show potential for producing at levels




Fig 6. Comparing cell line DNA copy number to RNA expression for tRNA^{pyl} and pylRSwt assays. Copy numbers of pylRS and tRNA were determined in six amber suppression competent cell lines. (A) The calculated DNA copy numbers plotted relative to the corresponding RNA expression levels. A loose correlation between copy number and expression is observed for pylRSwt; however, tRNA expression levels do not seem to depend on copy number. (B) The GFP:RFP ratios plotted relative to corresponding RNA expression levels.

<https://doi.org/10.1371/journal.pone.0216356.g006>

consistent with manufacturing standards. These can be used with conventional fermentation facilities and methodologies, but require engineered cells, carefully selected for high amber suppression potential.

While it is clear that an orthogonal tRNA synthetase and its cognate tRNA must be expressed by the host cells, the expression levels of these genes required for efficient nnAA incorporation remain largely unknown. This is, in part, due to the difficulties in quantifying tRNA levels which previously relied largely on Northern analyses and more recently on molecular methods which require multiple enzymatic steps [20–22]. Hence, we have developed a qPCR-based method for the quantitation of tRNA^{pyl} and pylRS that enable the rapid characterization of cell lines. The assays described here show a > 5 log dynamic range and are

Table 7. Comparing cell line RNA expression of tRNA^{pyl} and pylRS to GFP:RFP ratio.

Clone	Expression Ratio		Geo Mean		GFP:RFP
	tRNA ^{pyl}	pylRS	GFP	RFP	ratio
A	1.11E+00	1.79e-03	114	1103	0.103
B	2.95E-01	5.58e-04	82	3054	0.027
C	8.07E-01	1.56e-03	158	506	0.312
D	5.45E-01	9.58e-04	149	1570	0.095
E	4.53E-01	7.32e-04	111	3829	0.029
F	8.36E-01	2.42e-03	148	456	0.325
Neg	ND	ND	14	931	0.015

Expression levels of tRNA^{pyl} and pylRS are reported relative to 18S rRNA. Geometric means of GFP and RFP were quantified by flow cytometry. ND, not detected.

<https://doi.org/10.1371/journal.pone.0216356.t007>

effective at quantifying both RNA and gDNA. Engineered cell lines functionally characterized for efficient nnAA incorporation, contained 4–22 copies of pylRS and 65–560 copies of tRNA. More impressively we noted that expression levels of the tRNA approached that of the ribosomal 18S rRNA. This expression level is over 1000-fold greater than pylRS and the endogenous Phe and Met tRNAs. This high level of tRNA may be necessary to compete with release factor (eRF1) for amber codon recognition. eRF1 mediates the process of protein termination by recognizing stop codons and promoting the release of the polypeptide chain by the ribosome [23–24]. Thus, high levels of tRNA^{pyl} are likely needed to compete for amber codon binding and readthrough. Indeed, cells with higher levels of pylRS and tRNA expression show improved amber suppression efficacy using a transiently expressed reporter construct. However, it should be noted that the assay provides a relative quantitation of tRNA^{pyl} and pylRS expression levels which is useful for the discrimination of cell lines. That said, analyses of technical replicates show consistent results suggesting that the qPCR method is both robust and reproducible (S2 Table).

Beyond quantifying the tRNA, qPCR allows us to examine the extent of tRNA^{pyl} processing. In our cells tRNA^{pyl} expression is under control of a PolIII promoter that regulates the expression of a transcript that requires both 3' and 5' processing that is required to generate functional tRNA^{pyl}. The assays developed here discriminate between unprocessed and mature (functional) tRNA^{pyl} allowing for an assessment of tRNA functionality. In the cells tested we observed ~90% mature tRNA indicating that processing of this tRNA is efficient despite the high expression levels. Overall, the methodology described provides us with a tool for the characterization of cells containing aaRS/tRNA based systems as well as a key metric for cell line selection. The analysis of six cell lines showed a relationship between copy number and expression levels. Two notable exceptions for tRNA^{pyl} indicate that site of integration influences expression of these genes and highlights that copy number alone is not a predictive metric for tRNA expression. In addition, we show that increased amber suppression efficacy is observed in cells with higher levels of the pylRS/tRNA^{pyl}. Future studies with additional cell lines or other platforms are needed to better establish this relationship. As we develop new engineered cell lines the minimal requirements of tRNA and pylRS for efficient nnAA incorporation at >1g/L yields of target will become evident. One area of import is the genetic stability of the pylRS/tRNA^{pyl} system which must support efficient amber suppression over 70 generations in a manufacturing setting. The assay developed here is an invaluable tool in assessing the genetic stability of the system considering the highly repetitive nature of the tRNA^{pyl} cassettes and their potential for recombination. Overall the assay is readily applicable to the quantitation

of exogenous aaRS/tRNAs and offers a tool to better understand the limitations of these nnAA incorporation systems.

Supporting information

S1 Table. Data table examining the specificity of the qPCR assays.

(DOCX)

S2 Table. Data table examining the reproducibility of the qPCR assays.

(DOCX)

Author Contributions

Conceptualization: Andrew Garcia, Christine Kiefer, Marcello Marelli.

Formal analysis: Andrew Garcia, Marcello Marelli.

Investigation: Andrew Garcia, Gargi Roy.

Methodology: Andrew Garcia.

Supervision: Susan Wilson, Marcello Marelli.

Writing – original draft: Marcello Marelli.

Writing – review & editing: Gargi Roy, Marcello Marelli.

References

1. Hu QY, Berti F, Adamo R. Towards the next generation of biomedicines by site-selective conjugation. *Chemical Society Reviews*. 2016; 45: 1691–719. <https://doi.org/10.1039/c4cs00388h> PMID: 26796469
2. Hallam TJ, Wold E, Wahl A, Smider V V. Antibody conjugates with unnatural amino acids. *Mol Pharm*. 2015; 12: 1848–1862. <https://doi.org/10.1021/acs.molpharmaceut.5b00082> PMID: 25898256
3. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. *Clin cancer Res*. 2004; 10: 7063–70. <https://doi.org/10.1158/1078-0432.CCR-04-0789> PMID: 15501986
4. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. *Nat Biotechnol*. 2008; 26: 925–32. <https://doi.org/10.1038/nbt.1480> PMID: 18641636
5. Wang A, Nairn N, Marelli M, Grabstein K. Protein engineering with non-natural amino acids. In: Kaurmaya P, editor. *InTechOpen*; 2012; 253–90. <https://doi.org/10.5772/28719> Available from: <https://www.intechopen.com/books/protein-engineering/protein-engineering-with-non-natural-amino-acids>.
6. Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, et al. A general approach to site-specific antibody drug conjugates. *Proc Natl Acad Sci U S A*. 2014; 111: 1766–71. <https://doi.org/10.1073/pnas.1321237111> PMID: 24443552
7. VanBrunt MP, Shanebeck K, Caldwell Z, Thompson P, Martin T, Dong H, et al. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody – Drug Conjugates Using Click Cycloaddition Chemistry. *Bioconj Chem*. 2015; 26: 2249–2260 <https://doi.org/10.1021/acs.bioconjchem.5b00359> PMID: 26332743
8. Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, et al. Production of site-specific antibody–drug conjugates using optimized non-natural amino acids in a cell-free expression system. *Bioconj Chem*. 2014; 25: 351–61. <https://doi.org/10.1021/bc400490z> PMID: 24437342
9. Li X, Liu Z, Dong S. Bicyclo[6.1.0]nonyne and tetrazine amino acids for Diels–Alder reactions. *RSC Adv*. 2017; 7: 44470–3. <https://doi.org/10.1039/C7RA08136G>
10. Plass T, Milles S, Koehler C, Schultz C, Lemke EA. Genetically encoded copper-free click chemistry. *Angew Chem Int Ed Engl*. 2011; 50: 3878–81. <https://doi.org/10.1002/anie.201008178> PMID: 21433234
11. Wan W, Tharp JM, Liu WR. Pyrrolysyl-tRNA synthetase: an ordinary enzyme but an outstanding genetic code expansion tool. *Biochim Biophys Acta*. 2014; 1844: 1059–70. <https://doi.org/10.1016/j.bbapap.2014.03.002> PMID: 24631543

12. Xie J, Schultz PG. A chemical toolkit for proteins—An expanded genetic code. *Nature Reviews Molecular Cell Biology*. 2006; 7: 775–82. <https://doi.org/10.1038/nrm2005> PMID: 16926858
13. Nguyen DP, Lusic H, Neumann H, Kapadnis PB, Deiters A, Chin JW. Genetic encoding and labeling of aliphatic azides and alkynes in recombinant proteins via a pyrrolysyl-tRNA Synthetase/tRNA(CUA) pair and click chemistry. *J Am Chem Soc*. 2009; 131: 8720–1. <https://doi.org/10.1021/ja900553w> PMID: 19514718
14. Kiick KL, Saxon E, Tirrell DA, Bertozzi CR. Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. *Proc Natl Acad Sci*. 2002; 99: 19–24. <https://doi.org/10.1073/pnas.012583299> PMID: 11752401
15. Hancock SM, Uprety R, Deiters A, Chin JW. Expanding the genetic code of yeast for incorporation of diverse unnatural amino acids via a pyrrolysyl-tRNA synthetase/tRNA pair. *J Am Chem Soc*. 2010; 132: 14819–24. <https://doi.org/10.1021/ja104609m> PMID: 20925334
16. Mukai T, Kobayashi T, Hino N, Yanagisawa T, Sakamoto K, Yokoyama S. Adding l-lysine derivatives to the genetic code of mammalian cells with engineered pyrrolysyl-tRNA synthetases. *Biochem Biophys Res Commun*. 2008; 371: 818–22. <https://doi.org/10.1016/j.bbrc.2008.04.164> PMID: 18471995
17. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. *Proc Natl Acad Sci U S A*. 2012; 109: 16101–6. <https://doi.org/10.1073/pnas.1211023109> PMID: 22988081
18. Hopper AK, Pai DA, Engelke DR. Cellular dynamics of tRNAs and their genes. *FEBS Letters*. 2010; 584: 310–7. <https://doi.org/10.1016/j.febslet.2009.11.053> PMID: 19931532
19. Serfling R, Lorenz C, Etzel M, Schicht G, Böttke T, Mörl M, et al. Designer tRNAs for efficient incorporation of non-canonical amino acids by the pyrrolysine system in mammalian cells. *Nucleic Acids Res*. 2018; 46: 1–10. <https://doi.org/10.1093/nar/gkx1156> PMID: 29177436
20. Kohrer C, Sullivan EL, RajBhandary UL. Complete set of orthogonal 21st aminoacyl-tRNA synthetase-amber, ochre and opal suppressor tRNA pairs: concomitant suppression of three different termination codons in an mRNA in mammalian cells. *Nucleic Acids Res*. 2004; 32: 6200–11. <https://doi.org/10.1093/nar/gkh959> PMID: 15576346
21. Park H, Davidson E, King MP. Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene. *RNA*. 2008; 14: 2407–16. <https://doi.org/10.1261/rna.1208808> PMID: 18796578
22. Honda S, Shigematsu M, Morichika K, Telonis AG, Kirino Y. Four-leaf clover qRT-PCR: A convenient method for selective quantification of mature tRNA. *RNA Biol*. 2015; 12: 501–8. <https://doi.org/10.1080/15476286.2015.1031951> PMID: 25833336
23. Wong LE, Li Y, Pillay S, Frolova L, Pervushin K. Selectivity of stop codon recognition in translation termination is modulated by multiple conformations of GTS loop in eRF1. *Nucleic Acids Res*. 2012; 40: 5751–65. <https://doi.org/10.1093/nar/gks192> PMID: 22383581
24. Kryuchkova P, Grishin A, Eliseev B, Karyagina A, Frolova L, Alkalaeva E. Two-step model of stop codon recognition by eukaryotic release factor eRF1. *Nucleic Acids Res*. 2013; 41: 4573–86. <https://doi.org/10.1093/nar/gkt113> PMID: 23435318